Breaking News Instant updates and real-time market news.

AXDX

Accelerate Diagnostics

$23.30

-0.5 (-2.10%)

13:11
02/17/17
02/17
13:11
02/17/17
13:11

Accelerated Diagnotics attracts a far downside put spread

Accelerated Diagnotics attracts a far downside put spread. 7.6K Feb 5 puts sold at a penny and 7.6K Mar 12.5 puts bought for 38c. The spread has traded more than 12K and trade history shows the Feb 5 puts, which have 12.5K of open interest and are expiring today, were opened for 10 to 16c on 11/15/16 with the stock near $21.50. Shares are up 17c to $23.47 and the investor is now opening a new position in 46% out of the money Mar 12.5 puts. 5.2K Mar 12.5 puts were opened yesterday as well.

AXDX Accelerate Diagnostics
$23.30

-0.5 (-2.10%)

03/24/16
JPMS
03/24/16
INITIATION
Target $17
JPMS
Overweight
Accelerate Diagnostics initiated with an Overweight at JPMorgan
JPMorgan analyst Tycho Peterson started Accelerate Diagnostics with an Overweight rating and $17 price target. The company is well positioned to execute a successful commercial launch of the Accelerate ID/AST System and rapidly grow its install base, Peterson tells investors in a research note.
03/24/16
03/24/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Accelerate Diagnostics (AXDX) initiated with an Overweight at JPMorgan by analyst Tycho Peterson, who said the company is well positioned to execute a successful commercial launch of the Accelerate ID/AST System and rapidly grow its install base. 2. Envestnet (ENV) initiated with a Buy at Jefferies with analyst Surinder Thind saying he expects continued market share gains for the company and views its Yodlee acquisition as transformational. 3. Pure Storage (PSTG) initiated with an Outperform at William Blair by analyst Jason Ader, who sees an attractive risk/reward equation relative to the company's growth profile. 4. PayPal (PYPL) initiated with a Neutral at Sterne Agee CRT with analyst Moshe Katri citing rich valuation and long-term potential risks to its dominant position in eCommerce. 5. Wells Fargo (WFC) initiated with a Sell at UBS by analyst Brennan Hawken, who believes risks to Wells' revenue growth and credit performance are not reflected in the current valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/16
PIPR
04/11/16
NO CHANGE
Target $25
PIPR
Overweight
Piper still expects FDA approval for Accelerate Diagnostics in Q3
After Accelerate Diagnostics updated its investor deck with preliminary data from its FDA clinical trial, Piper Jaffray analyst William Quirk says he continues to expect FDA approval in Q3. The company announced "generally positive" preliminary FDA clinical trial results with AST data in line with the preclinical trial, Quirk tells investors in a research note. Accelerate's ID sensitivity of 94.6%, below the 95% endpoint and 96.6% from the preclinical trial, is unlikely to impact FDA approval given the "strong" AST results and faster turnaround time versus current systems, the analyst contends. He reiterates an Overweight rating on Accelerate Diagnostics with a $25 price target.
05/26/16
PIPR
05/26/16
NO CHANGE
PIPR
Piper sees limited impact from new European device tax rules
Piper Jaffray analyst William Quirk points out that the European Union announced it will issue new rules for medical devices and in vitro diagnostics in the near-to-mid term. The EU is looking to strengthen rules for clearing devices/tests for the market and increase existing device/test surveillance, Quirk tells investors in a research note. He believes the new rules should not inhibit well validated tests/devices from coming to market. As such, Quirk expects little impact to Piper's in vitro diagnostic coverage universe, namely Accelerate Diagnostics (AXDX), Becton Dickinson (BDX), Cepheid (CPHD), Hologic (HOLX), Quidel (QDEL) and Meridian Bioscience (VIVO).

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.